A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures

British Journal of Cancer

Volumn 105, Issue 9, 2011, Pages 1370-1378

  Sandanayake, N S ^a,b   Sinclair, J ^a   Andreola, F ^a   Chapman, M H ^a,c   Xue, A ^b   Webster, G J ^a,c   Clarkson, A ^d   Gill, A ^d   Norton, I D ^d   Smith, R C ^b   Timms, J F ^a   Pereira, S P ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

biliary tract cancer; IAC; interleukin 6; leucine rich a 2 glycoprotein; PSC; serum proteomic profiling

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; IMMUNOGLOBULIN G4; INTERLEUKIN 6; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT OBSTRUCTION; BILIARY TRACT CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; CHOLANGITIS; CHOLANGITIS, SCLEROSING; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 80054992678     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.376     Document Type: Article

References (50)

1. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S, Granath F, Broome U (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321-327 (Pubitemid 34194790)
2. Braconi C, Swenson E, Kogure T, Huang N, Patel T (2011) Targeting the IL-6 dependent phenotype can identify novel therapies for cholangio-carcinoma. PLoS One 5: e15195
3. Broome U, Lofberg R, Veress B, Eriksson LS (1995) Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22: 1404-1408
4. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610-615 (Pubitemid 26111384)
5. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD (2004) Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangi-tis. Am J Gastroenterol 99: 523-526 (Pubitemid 38524134)
6. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H (2000) Cholangiocarci-noma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31: 7-11 (Pubitemid 30033681)
7. Chan HL, Gharbi S, Gaffney PR, Cramer R, Waterfield MD, Timms JF (2005) Proteomic analysis of redox-and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine-and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics 5: 2908-2926 (Pubitemid 41059768)
8. Chapman RW (1999) Risk factors for biliary tract carcinogenesis. Ann Oncol 10(Suppl 4): 308-311
9. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S (1980) Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21: 870-877 (Pubitemid 11198911)
10. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD (2008) Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (Baltimore, Md) 48: 1106-1117
11. Chari ST (2007) Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic0 s HISORt criteria. J Gastroenterol 42(Suppl 18): 39-41 (Pubitemid 46863936)
12. Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, Lee MS, Lee JS, Shim CS (2007) Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 102: 2164-2170 (Pubitemid 47493842)
13. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR (2009) High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 50: 158-164
14. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341: 1368-1378
15. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007) Cholangiocarcino-ma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245: 755-762 (Pubitemid 46684105)
16. Gerhards MF, Vos P, van Gulik TM, Rauws EA, Bosma A, Gouma DJ (2001) Incidence of benign lesions in patients resected for suspicious hilar obstruction. Br J Surg 88: 48-51 (Pubitemid 32066056)
17. Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, Timms JF (2002) Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 1: 91-98
18. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE (1998) Marked elevation of serum interleukin-6 in patients with cholangiocar-cinoma: validation of utility as a clinical marker. Ann Surg 227: 398-404 (Pubitemid 28131021)
19. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512 (Pubitemid 41540626)
20. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ (2007) Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 132: 384-396 (Pubitemid 46108750)
21. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234: 507-517; discussion 517-519
22. Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Yamada T, Kato H, Nishimura T, Todo S, Hirohashi S (2007) Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 852: 257-267 (Pubitemid 46830120)
23. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H (2002a) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6): VI1-VI9 (Pubitemid 35216840)
24. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC (2002b) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37: 806-813 (Pubitemid 35404220)
25. Kornfeld D, Ekbom A, Ihre T (1997) Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41: 522-525
26. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, Goggins MG, Maitra A, Pandey A (2004) A proteomic analysis of human bile. Mol Cell Proteomics 3: 715-728 (Pubitemid 39077002)
27. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD (2005) The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 50: 1734-1740 (Pubitemid 41203674)
28. Lin Y, Dynan WS, Lee JR, Zhu ZH, Schade RR (2009) The current state of proteomics in GI oncology. Dig Dis Sci 54: 431-457
29. Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, Purvine SO, Camp II DG, Smith RD (2006) Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 5: 2167-2174 (Pubitemid 44817028)
30. Nagorney DM, Kendrick ML (2006) Hepatic resection in the treatment of hilar cholangiocarcinoma. Adv Surg 40: 159-171 (Pubitemid 44648288)
31. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1996) Cholangiocarci-noma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224: 463-473; discussion 473-5
32. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R (1999) Extended resections for hilar cholangiocarci-noma. Ann Surg 230: 808-818; discussion 819
33. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A (1994) Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 9: 462-467 (Pubitemid 24312840)
34. Park J, Tadlock L, Gores GJ, Patel T (1999) Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30: 1128-1133 (Pubitemid 29510848)
35. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95: 204-207 (Pubitemid 30041560)
36. Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, Mottaz HM, Varnum SM, Camp II DG, Huang L, Fang X, Zhang WW, Smith RD (2008) Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 7: 1963-1973
37. Reddy SB, Patel T (2006) Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 8: 30-37
38. Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC (2006) Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology 44: 658-666 (Pubitemid 44433722)
39. Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125 (Pubitemid 38738341)
40. Shaib YH, Davila JA, McGlynn K, El-Serag HB (2004) Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 40: 472-477 (Pubitemid 38230849)
41. Shirai R, Hirano F, Ohkura N, Ikeda K, Inoue S (2009) Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun 382: 776-779
42. Sinclair J, Metodieva G, Dafou D, Gayther SA, Timms JF (2011) Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. J Proteomics 74: 451-465
43. Steinberg W (1990) The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85: 350-355 (Pubitemid 20140602)
44. Sugawara H, Yasoshima M, Katayanagi K, Kono N, Watanabe Y, Harada K, Nakanuma Y (1998) Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 33: 145-153 (Pubitemid 28387024)
45. Tangkijvanich P, Thong-ngam D, Theamboonlers A, Hanvivatvong O, Kullavanijaya P, Poovorawan Y (2004) Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepato-Gastroenterology 51: 15-19 (Pubitemid 38283051)
46. Wang X, Dai S, Zhang Z, Liu L, Wang J, Xiao X, He D, Liu B (2009) Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care (Engl) 18: 625-635
47. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 66: 10517-10524 (Pubitemid 44799774)
48. Yamagiwa Y, Meng F, Patel T (2006) Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci 78: 2494-2502
49. Yan L, Tonack S, Smith R, Dodd S, Jenkins RE, Kitteringham N, Greenhalf W, Ghaneh P, Neoptolemos JP, Costello E (2009) Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res 8: 142-148
50. Yokomuro S, Tsuji H, Lunz III JG, Sakamoto T, Ezure T, Murase N, Demetris AJ (2000) Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 32: 26-35 (Pubitemid 30432362)